Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.32 |
| ▸ | CA1 | P00915 | 5/20 | 0.32 |
| ▸ | CA9 | Q16790 | 5/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23732249 | 0.84 | KDM4E (0.32) | KDM4E | |
| SCHEMBL23732262 | 0.80 | ALDH1A1 (0.38) | KDM4EALDH1A1HPGDHSD17B10CA2 | |
| SCHEMBL23127817 | 0.79 | KMT2A (0.43) | KDM4EALDH1A1HPGDCA2CA1 | |
| SCHEMBL23127818 | 0.75 | KDM4E (0.31) | KDM4EALDH1A1HPGDHSD17B10CA2 | |
| SCHEMBL23732218 | 0.74 | KMT2A (0.46) | KDM4EALDH1A1HPGDCA2CA1 | |
| SCHEMBL9196319 | 0.72 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDHSD17B10CA2 | |
| SCHEMBL23732255 | 0.71 | CA1 (0.40) | ALDH1A1HPGDHSD17B10CA2CA1 | |
| SCHEMBL23732264 | 0.69 | MAPT (0.32) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL23732191 | 0.68 | USP2 (0.34) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23732193 | 0.67 | USP2 (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236463-A1 | beta-LACTAMASE INHIBITOR | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236463-A1 | beta-LACTAMASE INHIBITOR | MGAM, CMBL, MGAM2 | KDM4E 1714/4885ALDH1A1 683/4885HPGD 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.